Literature DB >> 15456431

Lymph node metastasis of gastric cancer: comparison of Union International Contra Cancer and Japanese systems.

Masahide Ikeguchi1, Daiki Murakami, Shingo Kanaji, Shotaro Ohro, Yoshihiko Maeta, Ken-Ichi Yamaguchi, Shigeru Tatebe, Akira Kondo, Shun-Ichi Tsujitani, Nobuaki Kaibara.   

Abstract

BACKGROUND: The pN classification of gastric cancer (GC) in the Japanese system (Japanese Gastric Cancer Association; JGCA) is based on the site and distance of metastatic nodes from the primary tumour. Union International Contra Cancer (UICC) has recently proposed a classification system based on the number of nodes involved (TNM-1997). The aim of the present study is to assess which classification system is more suitable for providing a prognosis in advanced GC with lymph node metastasis.
METHODS: A total of 224 patients who underwent curative gastrectomy (R0: UICC-TNM and Resection A and B: JGCA) and D2 lymphadenectomy between 1990 and 1999, and diagnosed as pT2, pT3 and pT4 GC were enrolled. Patients were followed until the end of 2002. The disease-free survival rates of patients were compared between the two-stage systems (UICC-TNM and JGCA).
RESULTS: Using the JGCA system, there was a significant difference between the two survival curves (pN0 and pN1, P = 0.025; pN1 and pN2, P < 0.001; pN2 and pN3, P = 0.031), but the 5-year survival rate of 27 pN2 patients (32.7%) was not significantly different from that of 14 pN3 patients (34.3%, P = 0.994) using the UICC-TNM. In 47 patients with JGCA pN2, the 5-year survival rate of 18 patients with UICC-TNM pN1 (42.9%) was not significantly different from that of 18 patients with UICC-TNM pN2 (25.2%, P = 0.422) or from that of 11 patients with UICC-TNM pN3 (24.2%; P = 0.383).
CONCLUSIONS: The JGCA system is more suitable for estimating the prognosis of Japanese patients with advanced GC than the UICC-TNM.

Entities:  

Mesh:

Year:  2004        PMID: 15456431     DOI: 10.1111/j.1445-1433.2004.03188.x

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  7 in total

1.  Large metastatic lymph node size, especially more than 2 cm: independent predictor of poor prognosis in node-positive gastric carcinoma.

Authors:  O Cheong; S T Oh; B S Kim; J H Yook; J H Kim; J T Im; G C Park
Journal:  World J Surg       Date:  2008-02       Impact factor: 3.352

2.  A new pN staging system based on both the number and anatomic location of metastatic lymph nodes in gastric cancer.

Authors:  Jianhui Chen; Chuangqi Chen; Yulong He; KaiMing Wu; Hui Wu; Shirong Cai
Journal:  J Gastrointest Surg       Date:  2014-10-09       Impact factor: 3.452

3.  N stages of the seventh edition of TNM Classification are the most intensive variables for predictions of the overall survival of gastric cancer patients who underwent limited lymphadenectomy.

Authors:  Jingyu Deng; Rupeng Zhang; Yuan Pan; Baogui Wang; Liangliang Wu; Xishan Hao; Han Liang
Journal:  Tumour Biol       Date:  2013-11-29

4.  Validation of staging systems for gastric cancer.

Authors:  Keishi Yamashita; Shinichi Sakuramoto; Shiroh Kikuchi; Natsuya Katada; Nobuyuki Kobayashi; Masahiko Watanabe
Journal:  Gastric Cancer       Date:  2008-07-02       Impact factor: 7.370

5.  Transfusion alert for patients with curable cancer.

Authors:  Keishi Yamashita; Shinichi Sakuramoto; Shiroh Kikuchi; Natsuya Katada; Nobuyuki Kobayashi; Masahiko Watanabe
Journal:  World J Surg       Date:  2007-12       Impact factor: 3.282

6.  Comparison of five staging systems of lymph node metastasis in the gastric carcinoma.

Authors:  Ali Chehrei; Sakineh Amoueian; Jamshid Ansari; Mehdi Montazer; Mohammad Hossein Sanei
Journal:  J Res Med Sci       Date:  2013-10       Impact factor: 1.852

7.  Postoperative mortality and morbidity after D2 lymphadenectomy for gastric cancer: A retrospective cohort study.

Authors:  Giuseppe Brisinda; Maria Michela Chiarello; Anna Crocco; Neill James Adams; Pietro Fransvea; Serafino Vanella
Journal:  World J Gastroenterol       Date:  2022-01-21       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.